{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-001172","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2021-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.816927+00:00","generated_at":"2026-06-29T17:13:53.042474+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Janux Therapeutics Q2 net loss $6.2M; cash $394.2M post $222.9M IPO","bullets":["Completed $222.9M IPO in June and $125.0M Series B in April, total $347.9M in quarter.","Cash and short-term investments of $394.2M at June 30, 2021 vs $7.8M at Dec 31, 2020.","Q2 net loss of $6.2M, compared to $2.5M in same period 2020; R&D expense $4.7M.","On track to submit at least two INDs by end of 2022 for lead TRACTr programs.","Appointed Shahram Salek-Ardakani as CSO and Wayne Godfrey as CMO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-001172","json":"https://secwatch.observer/filing/0000950170-21-001172.json","markdown":"https://secwatch.observer/filing/0000950170-21-001172.md","text":"https://secwatch.observer/filing/0000950170-21-001172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017021001172/0000950170-21-001172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017021001172/janx-20210810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T17:13:53.042474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}